EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that on 19 December 2018, the Company was notified by Mike Salter (President, Americas) that he has today purchased 125,000 ordinary shares.
EKF Diagnostics announces an update in relation to its previously announced Buy-Back.
The Company's total issued share capital consists of 455,163,766 ordinary shares of 1 pence each with one voting right per share.
EKF Diagnostics announces an update to its prior announcement on 14 November 2018 in relation to the Buy-Back.
The Company confirms that on 20 November 2018, it purchased 1,641,493 of its ordinary shares on the London Stock Exchange at a price of 27.4348 pence per share. The purchased shares will be cancelled.
The Company confirms that on 19 November 2018, it purchased 178,423 of its ordinary shares on the London Stock Exchange at a price of 26.15 pence per share. The purchased shares will be cancelled.
EKF Diagnostics announces that RenalytixAI will be admitted to trading on AIM on 6 November 2018.
The Company is pleased to announce the results of the restricted offer made to its shareholders by Renalytix AI plc.
Following the release of the Company’s announcement on 22 October 2018, the Company provides the below update in relation to its planned distribution timetable.
Shareholder approval was received for a distribution in specie of shares in Renalytix AI plc to the Company's shareholders.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.